Oral non-Hodgkin's lymphomas (O-NHLs) are a rare group of diverse lymphoid tissue malignancies and represent less than 5% of the oral cavity malignancies and 2% of all extra-nodal NHLs. Oral-NHLs affect the Waldeyer'sring, the salivary glands, the bone of the jaws and the oral mucosa, their clinical appearance is very heterogeneous. Among the risk factors for NHLs are immunosuppression (primary or secondary), autoimmunity and inflammation. O-NHLs share the same risk factors. This case report describes a patient with O-NHL which was possibly linked to the combination of methotrexate and etanercept for the treatment of her rheumatoid arthritis. To our knowledge this is probably among the first cases of O-NHL with possible relation to the use of a Tumor Necrosis Factor (TNF) antagonist biological agent (etanercept). This case could contribute to the sensitization of the dentists for the signs and symptoms of this rare malignancy. It also underlines the need for thorough medical history and medication recording for all the dental patients.
Introduction
Non-Hodgkin's lymphomas [NHLs] are a heterogeneous group of lymphoid tissue malignancies accounting for at least 61 types of NHLs [WHO 2008 classification] (1). NHL has nearly doubled its incidence over the last 40 years becoming the fifth most common cancer (2, 3) . Lymphomas can occur outside the lymphatic system. The most common tissues of extra-lympatic/ extra-nodal origin are the mucosae [MALT lymphomas] especially of the gasrtointestinal tract and the skin [cutaneous lymphomas]. Extra-nodal involvement is identified in 30% of NHL cases (4) . The NHL involvement in the oral cavity represents the 2% of cases that occur in an extra-nodal environment and is the 3rd most common oral cancer (5), but accounts for less than 5% of oral cancers, as approximately 90% of oral cancers are squamous cell carcinomas (6) . NHLs in the oral cavity may affect sites where lymphoid tissue is present [tonsils, Waldeyer's ring], the major salivary glands, the jaws and also the oral mucosa (6) . The possibility for NHL increases as a result of uncommon immune-disorders such as hereditary disorders of immune dysfunction, HIV/AIDS, and organ transplantation, while other well-known risk factors comprise, infectious agents, a familial trait and autoimmune disorders (7) . Also there is a reported higher risk of lymphomas in patients treated with immune-modulating sorder of the oral soft tissue due to immune suppression. An immediate soft tissue biopsy [from the palatal surface] and orthopantomography were performed. The radiographic findings showed normal bone underneath the ulcer. The histological examination revealed lymphocytic infiltrate in hematoxylin eosin stain (Fig. 2) , and a panel of immunohistochemistry markers for lymphoma revealed positivity for the CD30 [cluster of differentiation ( Fig. 2) (Fig. 1) , and her rheumatoid arthritis is controlled only with low dose prednisolone.
Discussion
Despite the fact that etanercept has been labeled with a risk for NHL, the connection between the drug and the disease is still questionable (9) . In our case the patient had an excellent response and we could not ignore the fact that her response may be related to the cessation of etanercept, a clinical observation reported in the literature (10). In addition, the fact that etanercept was combi- (8) . Cases of lymphomas have been reported in adult patients with Rheumatoid arthritis and children with Juvenile idiopathic arthritis (9) , and the FDA added a black box label for this reason, but still questions remain whether etanercept risk for NHL is higher than that attributed to the underlying disease used for (9) .
Case Report
In this article we report a case of a 60 year old female patient with a ten year history of Rheumatoid arthritis treated with prednisolone 10mg/ daily, methotrexate 10mg /week, etanercept 25mg/weekly [for more than a year] and also risedronate sodium 35mg /weekly for prevention of osteoporosis. The main complaint of the patient was an ulcer with a 3 weeks reported duration, which caused moderate constant pain. She had done a full blood count and biochemical panel which showed no abnormal findings. She initially visited for this reason a general dentist who prescribed fluconazole and as the lesion did not resolve, she consulted an oral surgeon who suggested evaluation by an oral medicine specialist. The clinical examination revealed an ulcer with irregular margins covered with necrotic slough, located on the gingiva of the upper left quadrant [#25,#26], where the patient had an old bridge, (Fig. 1) and extended from the buccal to palatal surface. She had no palpable neck lymph nodes. According to the medical history and clinical findings the differential diagnosis, was : osteonecrosis, ulceration due to methotrexate, lymphoproliferative di-ned with methotrexate, another agent linked to NHL risk [especially those related to Epstein-Barr virus] enhances the possibility that her NHL is rather related to her long term immunosuppressive therapy rather than her disease (7). To our knowledge this is among the first [if not the first] reported cases of O-NHL possibly related to etanercept or other anti-TNF agent (11) . Patients with autoimmune diseases and long term immunosuppression should be informed to report their medical history to their dentist and the dentist should check their mouth for any unusual lumps or ulcers, as the clinical appearance of O-NHLs is highly atypical (6) . The physical exam should be completed with palpation of neck nodes. Any abnormal findings should be carefully evaluated. The fact the patient's dentist and oral surgeon did not attempt any extraction or periodontal surgery and suspected a non dental or periodontal cause for her ulcer contributed significantly to her excellent outcome (12) .
